Long-term efficacy and safety of elafibranor in primary biliary cholangitis: Interim results from the open-label extension of the ELATIVE trial up to 3 years

K V Kowdley, C L Bowlus, C Levy, U Akarca, M R Alvares-da-Silva, P Andreone, M Arrese, C Corpechot, H Elbeshbeshy, S Francque, M A Heneghan, P Invernizzi, I M Jacobson, D Jones, F C Kruger, E Lawitz, M J Mayo, M L Shiffman, M Sonderup, M G Swain, J M Valera,… · Zeitschrift für Gastroenterologie · 2025 · Heft 08 · S. e456-e457